Indaptus Therapeutics, Inc., a pre-clinical biotechnology company based in New York City, specializes in developing immunotherapy for unresectable or metastatic solid tumors and lymphomas. Their leading candidate, Decoy20, targets tumor and viral antigens using a platform that activates both innate and adaptive cellular immunity, delivered intravenously to target organs and tumors.
Indaptus Therapeutics (INDP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Indaptus Therapeutics's actual EPS was -$0.47, beating the estimate of -$0.55 per share, resulting in a 14.67% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
